Biotech \& Pharma Patent Law \& News Blog

## Court Report

By Sherri Oslick -- February 19, 2012


About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Merck \& Cie et al. v. Watson Pharmaceuticals, Inc. et al. 2:12-cv-00223; filed February 13, 2012 in the District Court of Nevada

- Plaintiffs: Merck \& Cie; Bayer Pharma AG; Bayer Healthcare Pharmaceuticals Inc.
- Defendants: Watson Pharmaceuticals, Inc.; Watson Laboratories Inc.


## Merck \& Cie et al. v. Watson Pharmaceuticals Inc. et al.

1:12-cv-00161; filed February 10, 2012 in the District Court of Delaware

- Plaintiffs: Merck \& Cie; Bayer Pharma AG; Bayer HealthCare Pharmaceuticals Inc.
- Defendants: Watson Pharmaceuticals Inc.; Watson Laboratories Inc.

The complaints in these cases are substantially identical. Infringement of U.S. Patent No. 6,441,168 ("Stable Crystalline Salts of 5-methyltetrahydrofolic Acid," issued August 27, 2002) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Merck's Beyaz® (drospirenone, 17aethinyl estradiol, and levomefolate calcium, used for oral contraception). View the Delaware complaint here.

## Senju Pharmaceutical Co. Ltd. et al. v. Apotex Inc. et al.

 1:12-cv-00159; filed February 10, 2012 in the District Court of Delaware- Plaintiffs: Senju Pharmaceutical Co. Ltd.; Kyorin Pharmaceutical Co. Ltd.; Allergan Inc.
- Defendants: Apotex Inc.; Apotex Corp.

Infringement of U.S. Patent Nos. 6,333,045 ("Aqueous Liquid Pharmaceutical Composition Comprised of Gatifloxacin," issued December 25, 2001) and 5,880,283 ("8-Alkoxyquinolonecarboxylic Acid Hydrate With Excellent Stability and Process for Producing the Same," issued March 9, 1999) following a Paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Allergan's Zymaxid® (gatifloxacin ophthalmic solution, used to treat bacterial conjunctivitis). View the complaint here.

## Panagene, Inc. v. Bio-Synthesis, Inc.

2:12-cv-00067; filed February 10, 2012 in the Eastern District of Texas
Infringement of U.S. Patent Nos. 6,395,474 ("Peptide Nucleic Acids," was issued May 28, 2002) and 7,378,485 ("Peptide Nucleic Acids with Polyamide-Containing Backbones," issued May 27, 2008) based on Biosyn's manufacture, use, and sale of Peptide Nucleic Acid compounds. View the complaint here.

[^0]
[^0]:    "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorneyclient relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

